| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.44 | 1-year : | 1.68 |
| Resists | First : | 1.23 | Second : | 1.44 |
| Pivot price | 1.09  |
|||
| Supports | First : | 0.89 | Second : | 0.74 |
| MAs | MA(5) : | 0.99 |
MA(20) : | 1.12 |
| MA(100) : | 0.96 |
MA(250) : | 0.9 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 10.2 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 1.9 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SSY ] has closed below upper band by 46.8%. Bollinger Bands are 106% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.21 - 1.22 | 1.22 - 1.22 |
| Low: | 0.94 - 0.95 | 0.95 - 0.95 |
| Close: | 1.1 - 1.11 | 1.11 - 1.12 |
Fri, 05 Dec 2025
SSY Group’s Finerenone Gains Approval in China, Boosting Market Position - TipRanks
Fri, 05 Dec 2025
Is NMPA’s Wave Of Drug Approvals Altering The Investment Case For SSY Group (SEHK:2005)? - simplywall.st
Thu, 04 Dec 2025
Bearish block trade of SSY GROUP(02005) 1.4M shares at $3.1, $4.34M turnover - AASTOCKS.com
Thu, 04 Dec 2025
SSY Group Secures Approval for New Pharmaceutical Products - TipRanks
Sat, 29 Nov 2025
SSY Group Secures Approval for New Drug Production in China - MSN
Fri, 14 Nov 2025
What next for Goran Rostad? Battle with SSY is set to rumble on - Tradewinds News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 28.3 (%) |
| Held by Institutions | 14.6 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.89 |
| Profit Margin | 5.5 % |
| Operating Margin | -9.4 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -22.4 % |
| Qtrly Rev. Growth | -1.9 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 4.41 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -2.86 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0.25 |
| Price to Cash Flow | -2.68 |
| Dividend | 0.01 |
| Forward Dividend | 0 |
| Dividend Yield | 1.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|